SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-139014
Filing Date
2020-05-11
Accepted
2020-05-11 16:02:40
Documents
14
Period of Report
2020-05-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d930076d8k.htm   iXBRL 8-K 26288
2 EX-99.1 d930076dex991.htm EX-99.1 48189
6 GRAPHIC g930076g0509081734529.jpg GRAPHIC 5271
  Complete submission text file 0001193125-20-139014.txt   214926

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cbay-20200511.xsd EX-101.SCH 3066
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cbay-20200511_lab.xml EX-101.LAB 18138
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cbay-20200511_pre.xml EX-101.PRE 11405
7 EXTRACTED XBRL INSTANCE DOCUMENT d930076d8k_htm.xml XML 3358
Mailing Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560
Business Address 7575 GATEWAY BOULEVARD SUITE 110 NEWARK CA 94560 510-293-8800
CymaBay Therapeutics, Inc. (Filer) CIK: 0001042074 (see all company filings)

IRS No.: 943103561 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36500 | Film No.: 20864681
SIC: 2834 Pharmaceutical Preparations